Increasing the options for effective migraine management.
Goadsby
P J
PJ
Institute of Neurology, London, UK.
Olesen
J
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D004878:Ergotamine / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones; D011788:Quality of Life; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use; D014363:Tryptamines
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000932:Antiemetics; D010080:Oxazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D018170:Sumatriptan; D004878:Ergotamine